LifeArc Ventures Scales Global VC Portfolio in Life Sciences
London, United Kingdom | January 29, 2026 — LifeArc Ventures, the venture capital arm of medical research organization LifeArc,...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
London, United Kingdom | January 29, 2026 — LifeArc Ventures, the venture capital arm of medical research organization LifeArc,...
Vancouver, British Columbia, December 18, 2025 — Restart Life Sciences Corp., a Canadian-based life sciences company, has successfully closed...
VANCOUVER, British Columbia — December 5, 2025 — Restart Life Sciences Corp. announced the successful closing of the first...
